Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prioritizing the proteome: identifying pharmaceutically relevant targets.

Mark B Swindells1, John P Overington

  • 1Inpharmatica, 60 Charlotte Street, London, UK W1T 2NU. m.swindells@inpharmatica.co.uk

Drug Discovery Today
|May 2, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New Machine Learning Models for Predicting the Organic Cation Transporters OCT1, OCT2, and OCT3 Uptake.

ACS omega·2025
Same author

Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma.

Cancer discovery·2021
Same author

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.

The Cochrane database of systematic reviews·2020
Same author

Artificial intelligence, drug repurposing and peer review.

Nature biotechnology·2020
Same author

Improving the odds of drug development success through human genomics: modelling study.

Scientific reports·2019
Same author

Setting Our Sights on Infectious Diseases.

ACS infectious diseases·2019
Same journal

Inorganic nanoparticles for diagnostics, drug delivery and therapy for solid tumors.

Drug discovery today·2026
Same journal

HDAC11 as a potential therapeutic target for Alzheimer's disease.

Drug discovery today·2026
Same journal

From biologics to small-molecule modulators: The evolving landscape of interleukin-targeted therapeutics.

Drug discovery today·2026
Same journal

Targeting the GLP-1 receptor pathways for dual management of obesity and depression.

Drug discovery today·2026
Same journal

Chemical intervention strategies targeting MYC for cancer therapy.

Drug discovery today·2026
Same journal

How many protein pairs can we chemically target?

Drug discovery today·2026
See all related articles

Prioritizing the proteome for drug discovery is challenging with incomplete data. This study links informatics and experimental methods to identify new drug targets, even within unknown protein families.

Area of Science:

  • Proteomics
  • Genomics
  • Bioinformatics
  • Drug Discovery

Background:

  • Genomic information is increasingly delivered via the proteome.
  • Pharmaceutical drug discovery faces challenges with incomplete proteome data.
  • Prioritizing drug targets requires effective analysis of proteomic information.

Purpose of the Study:

  • To describe challenges in proteome prioritization for pharmaceutical research.
  • To illustrate informatics-based proteome analysis using known drug targets.
  • To present methods for prioritizing drug targets in novel protein families.

Main Methods:

  • Informatics-based analysis of proteome data.
  • Integration of computational approaches with experimental techniques.

Related Experiment Videos

  • Utilizing single nucleotide polymorphism (SNP) data and disease pathways for prioritization.

    • Main Results:

    • Demonstrated informatics-based analysis of pharmaceutically relevant proteins.
    • Showcased methods to maximize results by combining informatics and experiments.
    • Presented strategies for prioritizing targets in unprecedented protein families.

    Conclusions:

    • Linking informatics and experimental methods enhances proteome prioritization for drug discovery.
    • Utilizing genomic and pathway data aids in identifying novel drug targets.
    • Effective prioritization strategies are crucial for pharmaceutical development from proteomic insights.